troglitazone has been researched along with Cancer of Gastrointestinal Tract in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We compared the effects of six types of TZDs (troglitazone, RS-1303, RS-1330, RS-1387, RS-1455, and RS-1456) and 9-cis RA, an RXRalpha ligand, on the activation of PPARgamma/RXRalpha and the growth inhibition of six types of adenocarcinoma cell lines (MKN45, HT-29, HCT116, HuCCT1, KMP-2, and BxPC3) established from abdominal malignancies." | 3.72 | Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway. ( Dono, K; Hayashi, N; Hiraoka, N; Monden, M; Nagano, H; Nakamori, S; Okami, J; Sakon, M; Tsujie, M; Umeshita, K, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsujie, M | 1 |
| Nakamori, S | 1 |
| Okami, J | 1 |
| Hayashi, N | 1 |
| Hiraoka, N | 1 |
| Nagano, H | 1 |
| Dono, K | 1 |
| Umeshita, K | 1 |
| Sakon, M | 1 |
| Monden, M | 1 |
1 other study available for troglitazone and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway.
Topics: Adenocarcinoma; Alitretinoin; Antineoplastic Agents; Apoptosis; Biliary Tract Neoplasms; Cell Differ | 2003 |